154,634 Shares in Dyne Therapeutics, Inc. $DYN Bought by Walleye Capital LLC

Key Points

• Walleye Capital LLC has acquired 154,634 shares of Dyne Therapeutics, Inc. for approximately $1.6 million, representing a 0.14% ownership stake in the company.
• CEO John Cox increased his ownership by 70.33% by purchasing 100,000 shares at an average price of $9.11 each, totaling $911,000.
• Analysts have mixed ratings on Dyne Therapeutics, with an average price target of $34.07 and several firms reducing their target prices for the stock recently.

Walleye Capital LLC purchased a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 154,634 shares of the company's stock, valued at approximately $1,617,000. Walleye Capital LLC owned approximately 0.14% of Dyne Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Atlas Venture Life Science Advisors LLC grew its holdings in Dyne Therapeutics by 13.9% during the 1st quarter. Atlas Venture Life Science Advisors LLC now owns 9,130,465 shares of the company's stock valued at $95,505,000 after buying an additional 1,111,111 shares in the last quarter. AlphaQuest LLC purchased a new position in Dyne Therapeutics during the 1st quarter valued at approximately $171,000. Candriam S.C.A. grew its holdings in Dyne Therapeutics by 15.4% during the 1st quarter. Candriam S.C.A. now owns 463,368 shares of the company's stock valued at $4,847,000 after buying an additional 61,973 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new position in Dyne Therapeutics during the 1st quarter valued at approximately $12,218,000. Finally, Hsbc Holdings PLC grew its holdings in Dyne Therapeutics by 112.6% during the 1st quarter. Hsbc Holdings PLC now owns 28,396 shares of the company's stock valued at $286,000 after buying an additional 15,042 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

Wall Street Analysts Forecast Growth

DYN has been the subject of several research analyst reports. JPMorgan Chase & Co. cut their price target on Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating for the company in a report on Tuesday, July 15th. Stifel Nicolaus cut their price target on Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating for the company in a report on Thursday, July 31st. Chardan Capital cut their price target on Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating for the company in a report on Tuesday, July 29th. Sanford C. Bernstein initiated coverage on Dyne Therapeutics in a report on Tuesday, June 24th. They issued a "market perform" rating and a $13.00 target price for the company. Finally, Royal Bank Of Canada dropped their target price on Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating for the company in a report on Tuesday, July 29th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $34.07.

Dyne Therapeutics Trading Down 1.0%

Shares of DYN stock traded down $0.14 on Wednesday, reaching $13.37. 1,324,115 shares of the company's stock were exchanged, compared to its average volume of 2,632,037. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $37.08. The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $1.90 billion, a PE ratio of -3.46 and a beta of 1.10. The company's fifty day simple moving average is $10.57 and its 200 day simple moving average is $11.15.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Monday, July 28th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.02. As a group, analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Activity at Dyne Therapeutics

In related news, CEO John Cox purchased 100,000 shares of Dyne Therapeutics stock in a transaction dated Monday, July 14th. The stock was purchased at an average cost of $9.11 per share, with a total value of $911,000.00. Following the transaction, the chief executive officer owned 242,179 shares in the company, valued at approximately $2,206,250.69. The trade was a 70.33% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 20.77% of the company's stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.